Ludwig Institute for Cancer Research Limited

Memorial Sloan Kettering Cancer Center

Institute of Molecular Biology and Genetics National Academy of Science of Ukraine

Sloan-Kettering Institute for Cancer Research

Institute for Molecular Biology and Genetics National Academy of Science of Ukraine

Institute of Molecular Biology and Genetics National Academy of Sciences of Ukraine

Serhiy Souchelnytskiy

Gerd J Ritter

Kenneth O Lloyd

Ivan Tarasovich Gout

Anne Murray

George Mark

Valeriy Filonenko

Beatrice Yin

Ramziya Kiyamova

Lloyd J Old

Lloyd Old

Ivan Gout

Viktorovich Filonenko

The present invention relates generally to the membrane transporter NaPi2b (SLC34A2) as a target for therapy, including immunotherapy, and particularly cancer therapy. The SLC34A2 epitope peptide encompassing amino acids 312-340 of SLC34A2 has been identified as an ovarian cancer epitope using the monoclonal antibody MX35. The invention also relates to the use of SLC34A2 and particularly SLC34A2 peptides in generating antibodies which have anti-tumor or anti-cancer activity or in stimulating an immunological response. The invention further relates to antibodies specifically directed against NaPi2b (SLC34A2) and the SLC34A2 peptide(s), including veneered, chimeric, single chain and humanized antibodies. Methods for generating an immune response and for treatment of tumors and cancer are also provided. Assays for screening and identifying compounds directed against SLC34A2, including the SLC34A2 epitope peptide, and additional antibodies are provided.

Antibodies directed to membrane transporter NaP12b (SLC34A2) and uses thereof in cancer therapy

Membrane transporter NaPi2b (SCL34A2) epitope for antibody therapy, antibodies directed thereto, and target for cancer therapy

The present disclosure relates generally to the membrane transporter NaPi2b (SLC34A2) as a target for therapy, including immunotherapy, and particularly cancer therapy. The SLC34A2 epitope peptide encompassing amino acids 312-340 of SLC34A2 has been identified as an ovarian cancer epitope using the monoclonal antibody MX35. The invention also relates to the use of SLC34A2 and particularly SLC34A2 peptides in generating antibodies which have anti-tumor or anti-cancer activity or in stimulating an immunological response. The invention further relates to antibodies specifically directed against NaPi2b (SLC34A2) and the SLC34A2 peptide(s), including veneered, chimeric, single chain and humanized antibodies. Methods for generating an immune response and for treatment of tumors and cancer are also provided. Assays for screening and identifying compounds directed against SLC34A2, including the SLC34A2 epitope peptide, and additional antibodies are provided.

Membrane transporter NaPi2b (SCL34A2) epitope antibodies

Membrane transporter NaPi2b (SCL34A1) epitope for antibody therapy, antibodies directed thereto, and target for cancer therapy

Growing community of inventors

Stockholm, Sweden

Serhiy Souchelnytskiy